- In this opposition appeal, the Board gives useful guidance about requests for acceleration of proceedings.
- More importantly, this valuable pharmaceutical patent is revoked essentially for insufficient disclosure of the second medical use due to lack of plausibility.
- " It follows from the above that in the present case it has to be examined whether the suitability of everolismus for the treatment of patients with PNETs has been shown or at least made plausible in the application taking into account the common general knowledge of the person skilled in the art."
- The Board then analyzes what the patent application discloses.
- " Paragraph [0052] provides nothing more than hypothetical statements indicating the possibility that some effects may be observed. The respondent's argument that the skilled reader would equate the expressions "may be observed" and "may be performed" with "had been observed" and "had been performed" and that the wording in paragraph [0052] was merely the inconsequential stylistic preference of the person drafting the application is not accepted."
- " The mere statement that chromogranin A reduction may be observed is not an indication that a clinical trial was on-going or that certain effects had actually been achieved. Moreover, in the absence of any information as to whether patients with PNETs have been treated or whether chromogranin A reduction actually correlates with tumour response in these patients, the mere statement that chromogranin A reduction may be observed is not sufficient to demonstrate the suitability of everolismus in the treatment of PNETs."
- " Paragraph [0053] of the patent in suit consists of a single sentence and states that "also synergistic effects of such combination are obtained" (i.e. the combination referred to in the preceding paragraph). Again this is a mere statement which is not supported by any factual evidence. "
- " It is the board's conviction that in these circumstances, where there existed no established relationship between mTOR inhibition and the treatment of PNETs, it was imperative to provide at least some technical evidence in the application as filed that allowed the skilled person to conclude that everolismus was suitable for the treatment of PNETs. A mere reference to the (desired) reduction of a biomarker that may be observed or a response evaluation that may be performed is not sufficient in this context."
- " The [patentee's] argument that it had been aware of intermediate results showing the suitability of everolismus in the treatment of PNETs, as the trial study reported in [D56] had already been on-going for several months before the earliest priority date, is not accepted. For sufficiency of disclosure, it is not relevant what the respondent was aware of, but decided not to disclose. "
- " Moreover, according to the [patentee's] own admission, the paragraphs on which it relied describe trials which had not yet been carried out and had not yet delivered any results. Indeed, the recruitment for a study of everolismus in monotherapy started well after the earliest priority date and the filing date of the patent in suit and results were apparently not available until several years later []. In the board's judgement, it is not justified to rely on knowledge which was acquired only after the relevant date to be used as a remedy for insufficiency of disclosure." Update 02.01.2018: the INN is "Everolimus" but the Board uses "everolismus". I've changed the title of this blog post to recite the INN.
EPO T 1868/16 - link
Reasons for the Decision
3. Accelerated processing
3.1 As a preliminary remark which, however, is not relevant for the present decision, the board would like to note that it regards acceleration of the appeal proceedings as well as postponement of oral proceedings to be matters pertaining to the conduct of the appeal proceedings which lies within the sole competence of the board. It might therefore be questioned whether the grant or refusal of a request for acceleration or postponement is at all a decision within the meaning of Article 111 EPC for which the board has to give its reasons pursuant to Rule 102 g) EPC. Nevertheless, in the present case, the board agreed to respond to the respondent's request for being given the board's reasons on acceleration.